The Royal Pharmaceutical society has welcomed the decision to reclassify Dovonex Psoriasis Ointment as a Pharmacy medicine. The Medicines and Healthcare products Regulatory Agency (MHRA) announced the POM to P switch on Thursday 17 August.

Dovonex Psoriasis Ointment contains calcipotriol, a vitamin D analogue, and is available in a 60g tube. It will be sold after a consultation with a pharmacist and is suitable for adults aged over 18 with mild to moderate plaque psoriasis that has been previously diagnosed by a doctor. It can be used for up to 12 weeks, after which people will be advised to see their doctor about ongoing treatment. 

Dr Sarah Branch, MHRA deputy director of vigilance and risk management of medicines, said: “Psoriasis is a chronic disease which can have a major impact on people’s quality of life. By making this medicine more widely available, patients will be able to treat flare ups quickly without the need for a prescription."

RPS president Ash Soni said: “Widening access to medicine is great news for patients. Pharmacists are already able to sell products for the treatment of psoriasis with appropriate advice on management, application and side effects. We welcome the addition of Dovonex Psoriasis Ointment to the range of products available.

“Pharmacists are more easily accessible than doctors and trained to give advice on medicine use, make sure the chosen medicine is appropriate and check if a person needs to see another health professional. This is an important patient benefit and we would like to see more medicine available through pharmacy in the future.”


Don’t forget March 31 deadline for clinical governance

The deadline for four clinical governance aspects of terms of service for contactors in England is fast approaching

Brexit negotiators urged to prioritise patient safety

The HDA joined the House of Commons’ Health and Social Care Committee in urging Brexit negotiators to prioritise p...